203 results
Page 3 of 11
6-K
EX-99.1
80uwdb 8f2d3fqj0ccrr
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
vnxmvbuxobbt gnwd1
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
2ohvg88h0dq8id3 bp8l
30 May 23
Current report (foreign)
6:11am
6-K
top0x5ng3wdtt5tq
17 May 23
Current report (foreign)
6:02am
6-K
adip3eya2ncern
11 May 23
Current report (foreign)
6:10am
6-K
l84y1symhwblmhqf
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
z1vez22w3o12h03h0mma
11 May 23
Current report (foreign)
6:07am
6-K
qggblclj r10n6
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
0vx47o
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
okumgraraf osh6pk
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
ekvkq77kgko
30 Nov 22
Current report (foreign)
6:28am
6-K
sopxdt6 8255
4 Nov 22
Current report (foreign)
6:01am
6-K
EX-99.1
0lvxh
27 Oct 22
Current report (foreign)
6:01am
6-K
edog1yeoksqfnwmopm
14 Oct 22
Current report (foreign)
7:36am
6-K
j9wf 4m8tv5
4 Oct 22
Current report (foreign)
6:06am
6-K
EX-99.1
t2xvtdkrs3ltrlg7
23 Aug 22
Current report (foreign)
6:13am
6-K
EX-99.1
s08thq
4 Aug 22
Current report (foreign)
6:07am
6-K
zk80zmjbuy87j7is yv
4 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
hlha2hw1 14h72zl5vhw
28 Jul 22
Current report (foreign)
6:09am
6-K
two0i2jj95oyk1omw
11 Jul 22
Current report (foreign)
6:05am